

## NCTN Sarcoma Trials Portfolio (Open as of 10/15/2026)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.




**Cross-disease trials:**




**Note: * ARST2032: only available for COG sites.**
**^ PEPN1924: open through the COG Pediatric Early Phase Clinical Trial Network (PEP-CTN) and patients must be enrolled at one of the PEP-CTN institutions.**
**Ref: https://dctd.cancer.gov/research/networks/pediatric**

# NCTN Sarcoma Trials (Open as of 10/15/2026)

| Protocol Number | Phase | Protocol Title |
|---|---|---|
| **AOST2031** | III | A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma |
| **AOST2032** | II/III | A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
| **ARST2032** | III | A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma |
| **ARST2531** | III | A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) Versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma |
| **EA7211** | III | A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2) |
| **EA7222** | III | A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas |
| **PEPN1924** | II | A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults with Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small round Cell Tumor |
| **S2505** | III | Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma |
| **EAY191** | Other | Molecular Analysis for Combination Therapy Choice (ComboMATCH) |
| **EAY191-N5** | II | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial |

**This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/**